These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 18927338)
1. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. Wadas TJ; Eiblmaier M; Zheleznyak A; Sherman CD; Ferdani R; Liang K; Achilefu S; Anderson CJ J Nucl Med; 2008 Nov; 49(11):1819-27. PubMed ID: 18927338 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy. Nguyen K; Parry JJ; Rogers BE; Anderson CJ Nucl Med Biol; 2012 Feb; 39(2):187-97. PubMed ID: 22056254 [TBL] [Abstract][Full Text] [Related]
3. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652 [TBL] [Abstract][Full Text] [Related]
4. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701 [TBL] [Abstract][Full Text] [Related]
5. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Guo Y; Ferdani R; Anderson CJ Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of a Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006 [TBL] [Abstract][Full Text] [Related]
7. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119 [TBL] [Abstract][Full Text] [Related]
8. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556 [TBL] [Abstract][Full Text] [Related]
9. Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line. Eiblmaier M; Andrews R; Laforest R; Rogers BE; Anderson CJ J Nucl Med; 2007 Aug; 48(8):1390-6. PubMed ID: 17631550 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of Re/ Radford LL; Papagiannopoulou D; Gallazzi F; Berendzen A; Watkinson L; Carmack T; Lewis MR; Jurisson SS; Hennkens HM Bioorg Med Chem; 2019 Feb; 27(3):492-501. PubMed ID: 30594453 [TBL] [Abstract][Full Text] [Related]
11. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. Lewis JS; Srinivasan A; Schmidt MA; Anderson CJ Nucl Med Biol; 1999 Apr; 26(3):267-73. PubMed ID: 10363797 [TBL] [Abstract][Full Text] [Related]
13. Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Edwards WB; Xu B; Akers W; Cheney PP; Liang K; Rogers BE; Anderson CJ; Achilefu S Bioconjug Chem; 2008 Jan; 19(1):192-200. PubMed ID: 18020401 [TBL] [Abstract][Full Text] [Related]
14. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET. Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735 [TBL] [Abstract][Full Text] [Related]
16. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate. Nedrow JR; White AG; Modi J; Nguyen K; Chang AJ; Anderson CJ Mol Imaging; 2014; 13():. PubMed ID: 25060207 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541 [TBL] [Abstract][Full Text] [Related]
18. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419 [TBL] [Abstract][Full Text] [Related]